LS CancerDiag Oy
Helsinki
About LS CancerDiag Oy
LS CancerDiag Ltd is committed to reducing cancer mortality rates with an efficient, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Funding stage: Seed
- Last round: Seed (Apr 2016)
- Website: lscancerdiag.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/ls-cancerdiag-oy-2434598 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.